International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1605-1611), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Diagnosis & Treatment of Cystic Fibrosis: A Review

Rehab Abdallah Yousif Mohammed

Abstract: **Current study was aimed to discuss and overview the diagnosis and treatment approaches of cystic fibrosis disease (CF), and intended also do highlight the etiology of this disease especially the role of genetics in CF. New treatments are being developed that have the possible to treat the causes, rather than just the symptoms, of CF lung disease. Detailed Search was conducted through Medical Databases; PubMed/ Medline, and Embase, searching relevant articles discussing the diagnostic approaches as well as treatment of cystic fibrosis, published in English language (as it was restricted applied) up to January, 2017. Moreover, we searched references lists of selected articles for more relevant studies that could been useful in this matter, and we restricted all search studies to human subject only. There is continuing development on treating the downstream elements of CF, such as sputum retention, airway infection, and inflammation, however our improving understanding of the underlying pathophysiology will help us target the early problems in CF, and early arise from studies of a number of substances look appealing. Dealing with the early and root causes of CF will improve results and hopefully also reduce the considerable burdens of treatment. It would be perfect to develop a "single hit" treatment and hence anticipate other treatments, however till that treatment is found, we continue to look for ways to reduce the development of the disease process.**

Keywords: **cystic fibrosis disease (CF), Downstream Elements.**

1. INTRODUCTION

Cystic fibrosis (CF) is an autosomal recessive, life-limiting disease arising from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) genetics. The genetics is included 27 exons and is positioned on chromosome 7. The healthy protein inscribed by the CFTR gene is a cAMP-regulated chloride channel positioned in the apical membrane of exocrine epithelial cells [(1)]; various other procedures with which it is involved include guideline of the epithelial salt network, as well as bicarbonate transportation. There is conflicting proof on its duty in regulating the pH of intracellular organelles and also the effects on mobile processes such as sialylation and also sulfation [(1,2)]. Historically, few patients with CF lived past early childhood years, however with continual renovation in treatment modalities, quality of life as well as the life span of individuals with CF has considerably improved [(2)].

Whilst the CFTR healthy protein is revealed in several interior body organs, the significant impact of such anomalies is on the respiratory system, intestinal, and reproductive systems, creating, in each of these sites, blockage by thick, thick secretions. Pulmonary disease results in a lot of the morbidity related to CF and is the cause of death in greater than 90% of patients [(2)]. The correlation of the molecular problem with this multi-system clinical photo is complex and also not entirely recognized. It has actually been revealed that CF airway epithelia have unusually high rates of sodium (and therefore water) absorption, which dries out the air passage surface liquid and also harms mucous transportation. Extra recently, vibrating society, which may recapitulate the in vivo setting much better than the standard fixed society version, has shown that these procedures are well preserved up until a "second hit" through viral infection happens [(3)]. Once the respiratory tract surface comes to be dried, mucociliary clearance (MCC) systems cannot eliminate any breathed in germs, which infect the reduced respiratory tracts and also lead to inflammation. The CF inflammatory response is unusual in several means, being exaggerated, prolonged and, at least in chronic phases of infection, futile, and also the waterfalls of CF lung disease displayed in (**Figure 1**) [(4,5)]. The presence of inflammatory cell materials such as DNA and elastase in the

air passage further increase mucous viscosity as well as contribute to tissue breakdown [6]. In the majority of instances, there is no problem in diagnosing CF. There may be broad variant in signs as well as signs and symptoms between individuals which encourage the clinical neighborhood to continuously boost the analysis examinations readily available and establish better methods to come to a last diagnosis in patients with milder phenotypes [7].

Current study was aimed to discuss and overview the diagnosis and treatment approaches of cystic fibrosis disease (CF), and intended also do highlight the etiology of this disease especially the role of genetics in CF.



Figure1: CF lung disease

2. METHODOLOGY

Detailed Search was conducted through Medical Databases; PubMed/ Medline, and Embase, searching relevant articles discussing the diagnostic approaches as well as treatment of cystic fibrosis, published in English language (as it was restricted applied) up to January,2017. Moreover, we searched references lists of selected articles for more relevant studies that could been useful in this matter, and we restricted all search studies to human subject only.

3. RESULTS

- **Aetiology of CF & Roles of Genetics in CF:**

Cystic fibrosis is an autosomal recessive disease. It is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) genetics [7]. The commonest anomaly is the removal of phenylalanine at codon 508. This occurs in around 70% of patients with cystic fibrosis The generally accepted description for air passage disease in cystic fibrosis is the "reduced quantity" hypothesis. A minimized volume of air passage surface area fluid causes failing of mucociliary clearance, the lungs' natural defense mechanism [8]. The mucociliary disorder implies that a patient with cystic fibrosis cannot efficiently clear inhaled bacteria. On top of that, there is an excessive inflammatory response to microorganisms. For a given microbial lots, a person with cystic fibrosis will have up to 10 times extra inflammation than a person with a reduced respiratory tract infection yet without the disease. This could additionally be the case for other insults such as infections or even for airborne particulate issue as well as toxins. The reasons for the too much inflammatory feedback to pathogens are not totally recognized. The irregular make-up as well as secretion of mucous may also be very important. At birth, the respiratory tract is possibly uninflamed and also clean, although some controversy exists in this area [9] (**Figure 2**).



Figure 2: Severe bronchiectasis in end stage cystic fibrosis shown in chest radiograph.

After the CFTR gene flaw was detected in 1989, it was anticipated that a restricted number of disease-causing mutations would cause CF [10,11]. By now more than 1,500 different anomalies have actually been explained, but it is very important to understand that the practical repercussions of much of these mutations are badly comprehended and most of these mutations are rare [11]. Less than 10 anomalies take place with a frequency of more than 1%, whereas the most common mutation worldwide, caused by a deletion of phenylalanine in position 508 (DF508) is discovered in approximately 66% of CF patients. CFTR mutations can be grouped into different classes based upon their functional effects on the CFTR within the cell: CFTR is either not synthesized (I), inadequately processed (II), not regulated (III), shows irregular conductance (IV), has partly malfunctioning production (V), or has accelerated destruction (VI) (**Figure 3**) [12,13]. The class I, II, and III mutations are more common and related to pancreatic deficiency, whereas patients with the less typical class IV, V, and VI mutations frequently are pancreatic enough. Far, the prognostic knowledge of the genetic mutation is of minimal medical worth, however this changed just recently since of the development of brand-new treatment methods that resolve specific aspects of CFTR dysfunction [14].



Figure 3: Classes of cystic fibrosis transmembrane regulator (CFTR) mutations

- **Diagnostic procedures of cystic fibrosis:**

Sweat tests and skin conductance for diagnosis of CF:

With increasing diagnostic difficulties and new candidate drugs for CF, there is a clear need for brand-new, easy and trusted biomarkers of faulty ion transport. Thus, the CF sweat duct is now being assessed utilizing assays aside from the standard sweat test for determining Cl − concentration [15]. The increased unfavorable bioelectric potential in the CF sweat duct can be assessed by transductal voltage measurement of promoted gland at the skin surface as explained by Gonska et al [16]. The sweat gland PD was determined during 30 minutes as the voltage in between 2 electrodes, one taped over a location of skin previously stimulated by iontophoresing pilocarpine, and the other inserted subcutaneously by needle puncture. Sweat gland PD resembled sweat Cl − concentration in comparing control and CF topics. Consecutive stimulation of sweating with cholinergic (by pilocarpine) and β-adrenergic agonists further improved the diagnostic performance of the test. The sweat duct can also be checked out by active electrophysiology, i.e. measurement of electrochemical skin conductance after application of a low direct existing voltage as described by Hubert et al. [17]. A low voltage is used in between 2 nickel electrodes on which the patient has actually put their feet or hands. This low voltage generates a present due to ion motions that in the skin originate from sweat duct pores. This current is measured and electrochemical skin conductance determined. The test is pain-free and takes less than 5 minutes. When control and CF subjects are studied, the assay offers a diagnostic uniqueness of 1 and a sensitivity of 0.93. To this day, proof-of-concept of these two new basic and useful real-time assays has actually just been shown in grownups. Results with these brand-new tests appear appealing and validate further development as result specifications in medical trials and as diagnostic tests for CF [17].

Diagnostic value of non-genetic blood tests: (Measurement of CFTR expression).

Genotyping is complex and it is frequently tough to interpret the determined anomalies. At present in vivo CFTR bio-assays are time consuming, troublesome and technically demanding. They are just offered in picked CF centres. There is thus excellent need for non-genetic blood tests that distinguish between CF and non CF topics. As an example we highlight methods.

Verloo et al. [18] were the first to recognize a CFTRlike direct chloride conductance in the plasma membrane of human erythrocytes that was activated upon Plasmodium falciparum infection and malfunctioning in CF patients. Stumpf et al. [19] checked out the presence of functional CFTR in human erythrocytes as a diagnostic test. The principle behind this test is the hemolysis of erythrocytes induced by gadolinium (Gd3+) ions. Erythrocytes from CF patients are more resistant to Gd3+- caused hemolysis than erythrocytes from healthy donors. In another approach, the authors demonstrated the differential Zn2+ sensitivity of Gd3+- caused hemolysis for non-CF and CF erythrocytes. Another approach recently proposed is based on the observation that leucocytes express noticeable levels of CFTR [20]. Utilizing immunoprecipitation and flow cytometry, Sorio et al. [21] offered initial data on CFTR expression and function ex vivo in leucocytes from healthy subjects and CF patients. Circulation cytometry, Western blotting and cell membrane depolarization was examined by single-cell fluorescence imaging utilizing the potential-sensitive probe bis-(1,3- diethylthiobarbituric acid) trimethine oxonol (DiSBAC2). The authors discovered greater levels of CFTR expression in monocytes and lymphocytes compared to polymorphonuclear cells [21]. The cell membrane depolarization assay demonstrated practical response only in monocytes from healthy controls and, to a lower degree, from obligate CF heterozygotes. Of significance, monocytes from CF patients revealed a completely various pattern of response permitting the right classification of healthy and diseased topics [21]. As a reference, the authors determined NPD in selected topics in parallel to the monocyte assay and constantly obtained constant results. These findings suggest that examination of CFTR expression and function in monocytes by circulation cytometry and optical strategies, respectively, may represent new techniques to identify CFTR dysfunction and assess the results of drugs on CFTR expression and function [21].

- **Treatment options of CF:**

Ivacaftor, an oral CFTR potentiator, considerably improved FEV1 and most secondary endpoints in children with CF 6--11 years of age who have a G551D-CFTR anomaly on a minimum of one allele. The results of this research study validate that the efficacy of ivacaftor shown formerly in grownups and adolescents reached this younger, healthier patient population [25]. Throughout the preparation of this manuscript, ivacaftor was authorized in the United States, Europe, and Canada for the treatment of CF in patients greater than or equal to 6 years of age who have a G551D anomaly. The enhancements in percent of predicted FEV1 were similar in magnitude to those seen in the trial of patients with CF greater than or equal to 12 years of age despite the fact that the children in the existing research study got in with less

disability in lung function than the adults and teenagers registered in the earlier trial, who had a mean FEV1 of 63.6%. Numerous children in the current study started with lung function within the normal variety and still displayed improvements in percent of forecasted FEV1 and other crucial secondary endpoints. In these children with CF, the mean treatment effect with ivacaftor through 24 weeks was an absolute enhancement of 12.5 percentage points of anticipated FEV1. Dornase alfa, which becomes part of the standard of care in CF, was related to a treatment result of 3.2 portion points in FEV1 at Week 96 in children 6 - 10 years of age in a clinical trial (26). Breathed in tobramycin, another standard-of-care CF therapy, resulted in a nonstatistically significant treatment effect relative to standard of 8.6% in FEV1versus placebo at Week 20 in a subgroup of children 6 - 12 years of age enrolled in a scientific study [(27)]. The majority of children in the current study were receiving these representatives (dornase alfa, 77%; tobramycin, 50%); therefore, the substantial treatment result of ivacaftor was accomplished within the setting of these continuous, standard-of-care medications. A contrast of modifications in pulmonary function observed in this trial and the earlier research study of ivacaftor in teenagers and young people [(25)] recommends a greater magnitude of improvement in this younger population.

Treatment of cystic fibrosis lung disease:

Conventional pulmonary treatment of CF has actually targeted the downstream repercussions of the disease, particularly mucus plugging and infection. The last couple of years have seen the development of more upstream therapeutic targets, several of which are in clinical trials, or have actually progressed to licensed treatments. Here, we discuss lung treatment options based on their mode of action, providing upgraded info on those in existing medical usage, and highlighting progress in research study. Treatments for other organs involved in CF (for example, the pancreas, liver, bones and sinuses) are outside the scope of this article but can be discovered in the work of Plant and colleagues [(22)]. The significance of optimal nutrition in respiratory health need to not be underestimated; evidence in support of this and an evaluation of the field can be discovered in a number of short articles [(23)]. Eventually, when medical treatment stops working, lung transplant is the only choice; this is a quickly expanding field, outside the scope of this post, however well evaluated by Lynch and coworkers [(24)]. The treatment modalities discussed in detail in this article are consisted in (**Table 1**).

Table 1: Treatment modalities in clinical use and clinical trials

Category	Approaches	Current status
Mucolytic agents	Dornase alfa	Role established in both adults and children
	N-acetyl-L-cysteine	No consensus of clinical utility
Airway surface rehydration	Hypertonic saline	Role established in adults, less marked results in children with ongoing studies
	Osmotic agents, mannitol	Adult phase III trials showed meaningful benefit. Phase II trials ongoing in children
	Correction of ion transport	P2Y2 receptor agonist, denufosol, failed to show replicable results in phase III trials
	ENaC blocker	P-1037 is currently in phase II clinical trials
Anti-infective agents	Prophylaxis	UK guidance for flucloxacillin, USA advises no prophylaxis, suggesting the need for further studies
	Eradication	Inhaled +/− systemic antibiotics, ongoing large European study comparing IV *versus* oral antibiotics
	Suppression	Nebulized antibiotics including tobramycin, colistin and aztreonam Amikacin currently under investigation
	Acute exacerbations	Oral or IV antibiotics
	Other bacterial organisms	AeroVanc in phase II trials for MRSA eradication AZLI recently shown in phase III trials to have no significant improvement in *Burkholderia* infections
	Other organisms	Current multicentre randomized double-blind control trial investigating Arikace in NTM. ABPA, oral antifungal agents and more recently omalizumab
	Nonantibiotic approaches	Current phase II trials of OligoG to treat chronic *pseudomonas* infection Multicentre trial ongoing exploring the benefit of IgY antibodies in *pseudomonal* infections.
Inflammation	Anti-inflammatory agents	Ibuprofen has been shown to have some benefit in young patients

		with mild disease in high doses.
	Inhaled corticosteroids	Inhaled corticosteroids have been shown to have little benefit
	LTB4 receptor antagonists	LTB4 phase II trials halted due to significant side effects
	Azithromycin	Possible modulation of the inflammatory system.
	Antioxidants	No clear benefit but warrants further work
CFTR protein defect	Potentiators	Ivacaftor in clinical use in patients over 6 years of age in Europe (with Asp551Gly mutation) and awaiting regulatory approval in the 2–5-year age bracket
	Correctors and combination therapy	Lumacaftor/ivacaftor treatment of patients with F508del mutations has finished phase III trials VX-661 is in phase III trials in combination with ivacaftor
	Read-through agents	Ataluren is currently in phase III trials
CFTR gene mutation	Gene therapy (nonviral and viral vectors)	Liposomal CFTR gene therapy has completed phase IIb clinical trials Preclinical work is ongoing on a pseudotyped lentivirus. QR010 is currently in phase Ib trials

4. CONCLUSION

Throughout the years considering that the CFTR gene was discovered, the evidence of principle of gene transfer to the air passage has actually been verified and partial correction in ion transport achieved. Amazing brand-new treatments are being developed that have the possible to treat the causes, rather than just the symptoms, of CF lung disease. There is continuing development on treating the downstream elements of CF, such as sputum retention, airway infection, and inflammation, however our improving understanding of the underlying pathophysiology will help us target the early problems in CF, and early arise from studies of a number of substances look appealing. Dealing with the early and root causes of CF will improve results and hopefully also reduce the considerable burdens of treatment. It would be perfect to develop a "single hit" treatment and hence anticipate other treatments, however till that treatment is found, we continue to look for ways to reduce the development of the disease process.

REFERENCES

[1] Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251–1254.

[2] Cystic Fibrosis Foundation. Patient Registry: Annual Data Report 2010. Bethesda, MD: Cystic Fibrosis Foundation; 2010.

[3] Tarran R, Button B, Picher M, et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem. 2005;280(42):35751–35759.

[4] Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med. 2002;165(7):911–915.

[5] Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol. 2004;5(4):388–392.

[6] Hartl D, Griese M, Kappler M, et al. Pulmonary T(H)2 response in *Pseudomonas aeruginosa*-infected patients with cystic fibrosis. J Allergy Clin Immunol. 2006;117(1):204–211.

[7] Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73.

[8] Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-15.

[9] Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51.

[10] Riordan JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245(4922): 1066-1073.

[11] Rommens JM, Iannuzzi MC, Kerem BS, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245(4922):1059-1065.

[12] Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256(5058):774-779.

[13] Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352(19):1992-2001.

[14] Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 2007;13(6):541-546.

[15] Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23(3):545–9.

[16] Gonska T, Ip W, Turner D, et al. Sweat gland bioelectrics differ in cystic fibrosis: a new concept for potential diagnosis and assessment of CFTR function in cystic fibrosis. Thorax 2009;64(11):932–8.

[17] Hubert D, Dusser D, Bry A, Fajac I. Evaluation of a new tool for measurement of sweat chloride concentration. Pediatr Pulmonol 2009;S32:269.

[18] Verloo P, Kocken CH, Van der Wel A, et al. Plasmodium falciparumactivated chloride channels are defective in erythrocytes from cystic fibrosis patients. J Biol Chem. 2004;279(11):10316–22.

[19] Stumpf A, Wenners-Epping K, Walte M, et al. Physiological concept for a blood based CFTR test. Cell Physiol Biochem 2006;17(1–2):29– 36.

[20] McDonald TV, Nghiem PT, Gardner P, Martens CL. Human lymphocytes transcribe the cystic fibrosis transmembrane conductance regulator gene and exhibit CF-defective cAMP-regulated chloride current. J Biol Chem 1992;267(5):3242–8.

[21] Sorio C, Buffelli M, Ettorre M, et al. Functional evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) expression function in human monocytes. J Cyst Fibros 2009;8:S22.

[22] Plant B., Goss C., Plant W., Bell S. (2013) Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 1: 164–174.

[23] Sanders D., Fink A., Mayer-Hamblett N., Schechter M., Sawicki G., Rosenfeld M., et al. (2015) Early life growth trajectories in cystic fibrosis are associated with pulmonary function at age 6 years. J Pediatr 167: 1081.e1–1088.e1.

[24] Lynch J., Sayah D., Belperio J., Weigt S. (2015) Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med 36: 299–320.

[25] Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672.

[26] Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW. Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139:813–820.

[27] Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al. Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999; 340:23–30.